Nanocarriers are fundamentally transforming targeted drug delivery (TDD) by addressing the major limitations of conventional therapies, such as systemic toxicity and poor drug localization. Th Show more
Nanocarriers are fundamentally transforming targeted drug delivery (TDD) by addressing the major limitations of conventional therapies, such as systemic toxicity and poor drug localization. These nanoscopic vehicles, including liposomes and polymeric nanoparticles, typically sized between 1 and 100 nanometers, are engineered to encapsulate, protect, and escort therapeutic agents until they reach the precise site of action. The key to their success lies in targeted delivery mechanisms. Passive targeting utilizes the enhanced permeability and retention (EPR) effect, where nanocarriers accumulate preferentially in leaky tumor vasculature. Active targeting involves surface modification with specific ligands (e.g., functional chemical/group, antibodies, or peptides) that bind to overexpressed receptors on diseased cells, ensuring high local drug concentration. This precision significantly boosts therapeutic efficacy while minimally affecting healthy tissues, leading to fewer side effects. This review provides an in-depth examination of TDD, highlighting how nanocarriers are essential in achieving precision and improving therapeutic outcomes. It explores the diverse strategies and suitable materials utilized to guide therapeutic agents specifically to disease sites while minimizing systemic toxicity.
Show less
Lung cancer is a common malignant tumor that occurs in the human body and poses a serious threat to human health and quality of life. The existing treatment methods mainly include surgical treatment, Show more
Lung cancer is a common malignant tumor that occurs in the human body and poses a serious threat to human health and quality of life. The existing treatment methods mainly include surgical treatment, chemotherapy, and radiotherapy. However, due to the strong metastatic characteristics of lung cancer and the emergence of related drug resistance and radiation resistance, the overall survival rate of lung cancer patients is not ideal. There is an urgent need to develop new treatment strategies or new effective drugs to treat lung cancer. Ferroptosis, a novel type of programmed cell death, is different from the traditional cell death pathways such as apoptosis, necrosis, pyroptosis and so on. It is caused by the increase of iron-dependent reactive oxygen species due to intracellular iron overload, which leads to the accumulation of lipid peroxides, thus inducing cell membrane oxidative damage, affecting the normal life process of cells, and finally promoting the process of ferroptosis. The regulation of ferroptosis is closely related to the normal physiological process of cells, and it involves iron metabolism, lipid metabolism, and the balance between oxygen-free radical reaction and lipid peroxidation. A large number of studies have confirmed that ferroptosis is a result of the combined action of the cellular oxidation/antioxidant system and cell membrane damage/repair, which has great potential application in tumor therapy. Therefore, this review aims to explore potential therapeutic targets for ferroptosis in lung cancer by clarifying the regulatory pathway of ferroptosis. Based on the study of ferroptosis, the regulation mechanism of ferroptosis in lung cancer was understood and the existing chemical drugs and natural compounds targeting ferroptosis in lung cancer were summarized, with the aim of providing new ideas for the treatment of lung cancer. In addition, it also provides the basis for the discovery and clinical application of chemical drugs and natural compounds targeting ferroptosis to effectively treat lung cancer. Show less